| Identification | Back Directory | [Name]
Firuglipel | [CAS]
1371591-51-3 | [Synonyms]
Firuglipel
4-(5-((R)-1-(4-(Cyclopropanecarbonyl)phenoxy)propyl)-1,2,4-oxadiazol-3-yl)-2-fluoro-N-((R)-1-hydroxypropan-2-yl)benzamide
Benzamide, 4-[5-[(1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl]-1,2,4-oxadiazol-3-yl]-2-fluoro-N-[(1R)-2-hydroxy-1-methylethyl]- | [Molecular Formula]
C25H26FN3O5 | [MDL Number]
MFCD31807598 | [MOL File]
1371591-51-3.mol | [Molecular Weight]
467.49 |
| Hazard Information | Back Directory | [Uses]
Firuglipel (DS-8500a) is an orally available, potent and selective GPR119 agonist. | [in vivo]
Firuglipel (DS-8500a) (1-30 mg/kg) upregulates glucagon-like peptide-1 and enhances glucose-dependent insulin secretion and improves glucose homeostasis in type 2 diabetic rats[1]. | [References]
[1] Matsumoto K, et al. DS-8500a, an Orally Available G Protein-Coupled Receptor 119 Agonist, Upregulates Glucagon-Like Peptide-1 and Enhances Glucose-Dependent Insulin Secretion and Improves Glucose Homeostasis in Type 2 Diabetic Rats. J Pharmacol Exp Ther. 2018 Dec;367(3):509-517. DOI:10.1124/jpet.118.250019 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|